| Literature DB >> 33344118 |
Bingbo Yu1, Bing Dong1, Jiang He1, Hui Huang2, Jinsheng Huang3, Yong Wang3, Jianwen Liang2, Jianning Zhang1, Yumin Qiu1, Jun Shen4, Xintao Shuai1,3, Jun Tao1, Wenhao Xia1.
Abstract
A major challenge to treatEntities:
Keywords: bimodal imaging; cardiovascular disease; endothelial progenitor cells; nanomedicine; vascular endothelial injury repairing
Year: 2020 PMID: 33344118 PMCID: PMC7740091 DOI: 10.1002/advs.202001657
Source DB: PubMed Journal: Adv Sci (Weinh) ISSN: 2198-3844 Impact factor: 16.806
Scheme 1Schematic illustrations of bimodal imaging‐visible nanomedicine (PEG‐PEI) integrating CXCR4 and VEGFa genes directs synergistic reendothelialization of endothelial progenitor cells.
Figure 1Characterization of cDNA plasmid‐complexed and SPION‐loaded nanoplex. A) Electrophoretic mobility of cDNA plasmid in agarose gel after complexing with mPEG‐PEI (NPs) and mPEG‐PEI/SPION (NPs‐SPION) at various N/P ratios. B) Particle size and zeta potential of nanoplexes at various N/P ratios. Data are shown as mean ± SD, n = 3. C) Morphology of nanoplex prepared at N/P 12 as measured by transmission electron microscope (TEM). Scale bar: 200 nm. D) Fluorescence microscopic images revealed pDNA (green) and nanocarrier (red) inside EPCs transfected with pDNA/NPs‐SPION. Scale bar: 2 µm. E) N/P ratio‐dependent transfection efficiency quantified using flow cytometry assay (n = 5).
Figure 2Cytotoxicity and cellular uptake. A,B) Cell viabilities and apoptosis rates detected by CCK8 and by flow cytometry at various N/P ratios in EPCs transfected with NPs and NPs‐SPION. Data are shown as mean ± SD, n = 3. C) T2‐weighted imaging (T2WI) and pseudocolored imaging of EPCs after incubation with NPs‐SPION at various Fe concentrations and time. D) Prussian staining (blue) microscopic images showed abundant iron particles inside EPCs transfected with NPs‐SPION in contrast to EPCs transfected with SPION‐free (NPs) control. Scale bar: 100 µm.
Figure 3In vitro gene expression regulation of EPCs. A,B) CXCR4 and VEGFa mRNA expression in EPCs transfected with Vector/NPs‐SPION(Vector), CXCR4/NPs‐SPION(CXCR4), VEGFa/NPs‐SPION(VEGFa), CXCR4‐VEGFa/NPs‐SPION(C‐V) and cells without treatment (CTRL). C) Representative photographs and D) quantification analyses of CXCR4 and VEGFa protein expressions in transfected EPCs assessed by Western blotting. E) Representative photographs and F) quantification analyses of CXCR4 and VEGFa protein expressions in transfected EPCs assessed by flow cytometry. G) Representative photographs and H) quantification analyses of CXCR4 and VEGFa protein expressions in transfected EPCs evaluated by laser confocal scanning microscopy (LCSM). Scale bar: 10 µm. Data are shown as mean ± SD, n = 5. **P < 0.01, ***P < 0.001.
Figure 4Migration and differentiation of EPCs enhanced by codelivery of CXCR4 and VEGFa genes. A) Migration (wound healing and transwell), adhesion, tube formation (Matrigel) of EPCs in different groups (five groups: CTRL, Vector, CXCR4, VEGFa, C‐V). B) EPCs proliferation (upper panel) and cell cycle (lower panel) of different groups. C,D) Immunofluorescent staining (C, Red: VE‐CAD; Green: E‐SEL) for endothelial cell markers and semiquantification D) on EPCs after 2 week culture in different groups. Scale bar: 10 µm. E–G) Histograms of flow cytometric analysis of cell markers on EPCs after 14 d culture in different groups. Data as mean ± SD, n = 5. *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: CTRL, cells without treatment; Vector, EPCs transfected with Vector/NPs‐SPION; CXCR4, EPCs transfected with CXCR4/NPs‐SPION; VEGFa, EPCs transfected with VEGFa/NPs‐SPION; C‐V, EPCs transfected with CXCR4‐VEGFa/NPs‐SPION; FCM, flow cytometry; VE‐CAD, vascular Endothelial‐Cadherin; E‐SEL, E‐ selectin.
Figure 5The synergy of CXCR4 and VEGFa genes codelivered into EPCs. A) Schematic illustration of the synergistic reendothelialization of combination therapy with CXCR4 and VEGFa genes transfected in EPCs. B) The mRNA expressions of related molecular targets in EPCs receiving CXCR4 and VEGFa codelivery quantified by qPCR analysis. Data are shown as mean ± SD, n = 3. *P < 0.05, **P < 0.01. C) The protein expressions of related molecular targets in EPCs receiving CXCR4 and VEGFa codelivery analyzed by Western blot. D) Density quantification of protein expression of related molecular targets in EPCs receiving CXCR4 and VEGFa codelivery. Abbreviations: PDGF, platelet derived growth factor; FGF, fibroblast growth factor; eNOS, endothelial nitric oxide synthase; AKT, protein kinase B; GAPDH, glyceraldehyde‐3‐phosphate dehydrogenase.
Figure 6In vivo effects of codelivered CXCR4 and VEGFa genes on migration and differentiation of EPCs. A) in vivo NIR optical imaging in different time points (days: 0, 1 and 2) and ex vivo fluorescence imaging of the separated carotid at day 2 after tail vein injection of transfected‐EPCs labeled with Cy7.5 into the right carotid injury nude rat. B) Average fluorescence signal quantification of the areas of interest shown in (A). C) Normalized ex vivo fluorescence intensity of the carotid separated at day 2 as shown in the right panel of (A). D) Coronal T2‐weighted MR images of the injured carotid artery of nude rat after injecting transfected‐EPCs at different time points (days: 0, 1, and 2). The right panel showed Prussian blue staining (PB staining) of the injured right carotid sections of different groups at day 2. The red arrows mark the SPION (blue). Scale bar: 10 µm. E) Normalized MRI T2 signal intensity of the injured carotid artery endothelium of nude rat after injecting transfected‐EPCs. F) Fluorescent assays indicating EPCs persistently expressing the red fluorescence protein mCherry (mEPCs) in the injured carotid sub‐endothelium at 3 d after transplantation. Scale bar: 20 µm. G) Quantitative assessment of EPC differentiation into endothelial cells (double positive for mCherry and Lectin) by flow cytometry. Data are shown as mean ± SD, n = 6. **P < 0.01,***P < 0.001.
Figure 7The therapeutic effect of transplanted EPCs in vivo. A) Representative T2WI serial MR imaging for coronary (upper three panel) and transverse (lower three panel) views of carotid sections at day 3 of different groups. The amplified and pseudocolored image of the dotted area is presented below. B,C) Reendothelialization areas on the injured carotid arteries of different groups by Evans blue staining. Denudated‐endothelium area was stained in blue; reendothelialization area was in white and its quantification (C). D) Representative micrographs of hematoxylin‐eosin (HE) staining of EC (upper panel), immunohistochemistry (IHC) staining of CD31 (middle panel) and immunofluorescence (IF) staining of αVβ3 (lower panel) in injured carotid of nude rats. Scale bar: 5 µm. E) Nitric oxide (NO) released from endothelial cells of injured carotid from different groups. F) The expression of phenylephrine induced vasoconstriction and the expression of vasorelaxation of carotid artery to acetylcholine stimulation assesses by Aortic vasorelaxation assay. Data are shown as mean ± SD, n = 6. **P < 0.01, ***P < 0.001.